NewAmsterdam Pharma (NAMS) Share-based Compensation (2023 - 2026)

NewAmsterdam Pharma has disclosed Share-based Compensation across 4 years of filings, most recently posting $18.0 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $18.0 million, up 18.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $62.2 million (up 52.06% YoY), and the FY2025 annual result was $59.4 million, up 76.76% from the prior year.
• Share-based Compensation came in at $18.0 million for Q1 2026 at NewAmsterdam Pharma, up from $14.0 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $18.0 million in Q1 2026 to a low of $5.4 million in Q3 2023.
• The 4-year median for Share-based Compensation is $8.3 million (2024), against an average of $10.4 million.
• Across the five-year window, Share-based Compensation gained 3.97% in 2024 and surged 92.13% in 2025, its largest moves.
• NewAmsterdam Pharma's Share-based Compensation stood at $6.0 million in 2023, then jumped by 56.76% to $9.4 million in 2024, then soared by 48.94% to $14.0 million in 2025, then increased by 28.37% to $18.0 million in 2026.
• The last three Share-based Compensation figures came in at $18.0 million (Q1 2026), $14.0 million (Q4 2025), and $15.0 million (Q3 2025), per Business Quant data.